• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Pharmacology and Pharmacotherapeutics >Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients
【24h】

Effects of atorvastatin and rosuvastatin on high-sensitivity C-reactive protein and lipid profile in obese type 2 diabetes mellitus patients

机译：阿托伐他汀和瑞舒伐他汀对肥胖2型糖尿病患者高敏C反应蛋白和脂质谱的影响

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective:To evaluate and compare the effects on high-sensitivity C-reactive protein (hs-CRP) levels and lipid profile of atorvastatin and rosuvastatin in obese type 2 diabetes mellitus (T2DM) patients.Materials and Methods:A total of 40 subjects with 20 in each group were randomly allocated to two groups. Group 1 patients received atorvastatin and that of Group 2 rosuvastatin treatment for 6 months. The patients were administered atorvastatin (40-80 mg) and rosuvastatin(10-40 mg) in accordance to their LDL-C status as per NCEP-ATP III guidelines. The parameters studied were, hs-CRP and lipid profile comprising LDL-C, HDL-C, TG and TC.Results:Results obtained from the study, clearly indicate that atorvastatin (A) as well as rosuvastatin(R) have significant effect on lowering of hs-CRP levels (for A P=0.001; for R P=0.002), reducing LDL-C levels (for A P=0.008; for R P=0.001), elevating HDL-C levels (for A P=0.02; for R P=0.001) along with reducing TC (for A P=0.003; for R P=0.002) and TG (for A P=0.000; for R P=0.000) levels in obese T2DM patients. It is also seen that there is no significant (P>0.05) difference in effect of atorvastatin and rosuvastatin in lowering of hs-CRP levels, elevating HDL-C levels and reducing TG levels in obese T2DM patients. However, percentage lowering of LDL-C (P=0.000) and TC (P=0.001) by rosuvastatin is to a greater extent than that caused by atorvastatin in these patients.Conclusions:Thus this study throws light on the fact that rosuvastatin should be preferred over atorvastatin in obese T2DM patients in whom LDL-C and TC levels are deviated from normal reference values. In rest of obese T2DM either of atorvastatin or rosuvastatin can be employed to lower hs-CRP levels, to elevate HDL-C levels or to reduce TG levels.
机译：目的：评价和比较肥胖2型糖尿病（T2DM）患者对阿托伐他汀和瑞舒伐他汀对高敏C反应蛋白（hs-CRP）水平和血脂谱的影响。材料与方法：共40例每组20只随机分配到两组。第1组患者接受阿托伐他汀治疗，第2组接受瑞舒伐他汀治疗6个月。根据NCEP-ATP III指南的LDL-C状态，患者接受阿托伐他汀（40-80 mg）和瑞舒伐他汀（10-40 mg）的治疗。研究的参数为hs-CRP和脂质分布，包括LDL-C，HDL-C，TG和TC。结果：研究结果清楚表明，阿托伐他汀（A）和rosuvastatin（R）对降低hs-CRP水平（对于AP = 0.001;对于RP = 0.002），降低LDL-C水平（对于AP = 0.008;对于RP = 0.001），提高HDL-C水平（对于AP = 0.02;对于RP = 0.001） ），同时降低肥胖T2DM患者的TC（对于AP = 0.003;对于RP = 0.002）和TG（对于AP = 0.000;对于RP = 0.000）水平。还发现在肥胖的T2DM患者中，在降低hs-CRP水平，升高HDL-C水平和降低TG水平方面，阿托伐他汀和罗苏伐他汀的作用没有显着差异（P> 0.05）。但是，瑞舒伐他汀在这些患者中降低LDL-C（P = 0.000）和TC（P = 0.001）的百分比的程度比阿托伐他汀引起的降低程度更大。结论：因此，本研究阐明了瑞舒伐他汀应该是肥胖的T2DM患者的LDL-C和TC水平偏离正常参考值时，首选阿托伐他汀。在其余肥胖的T2DM中，可以采用阿托伐他汀或瑞舒伐他汀中的任一种来降低hs-CRP水平，升高HDL-C水平或降低TG水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号